VRTX Q1 2021 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.7B+13.8% YoY

Gross Profit

$1.5B88.8% margin

Operating Income

$888M51.5% margin

Net Income

$653M37.9% margin

EPS (Diluted)

$2.49

QoQ Revenue Growth

+5.9%

Cash Flow

Operating Cash Flow

$921M

Free Cash Flow

$850M

Stock-Based Comp.

$115M

Balance Sheet

Total Assets

$12.1B

Total Liabilities

$3.1B

Stockholders' Equity

$9.0B

Cash & Equivalents

$6.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.7B	$1.5B	+13.8%
Gross Profit	$1.5B	$1.4B	+13.3%
Operating Income	$888M	$720M	+23.3%
Net Income	$653M	$603M	+8.4%

Revenue Segments

TRIKAFTA/KAFTRIO

$1.2B69%

ORKAMBI

$219M13%

KALYDECO

$186M11%

SYMDEKO/SYMKEVI

$125M7%

Geographic Segments

UNITED STATES

$1.3B73%

Europe

$405M23%

Other, Non U.S.

$65M4%